Related Experiment Video
Updated: May 25, 2026
04:00
Identifying Frailty Using Point-of-Care Ultrasonography: Image Acquisition and Assessment
Published on: July 26, 2024
Frailty and sarcopenia: definitions and outcome parameters.
1MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, England, UK. cc@mrc.soton.ac.uk
Summary
Defining sarcopenia and physical frailty is crucial for developing effective interventions. An operational definition should include muscle mass loss, decreased strength, and reduced physical activity for clinical validation and treatment inclusion.
Area of Science:
- Gerontology
- Musculoskeletal Health
- Aging Research
Background:
- Musculoskeletal decline, frailty, and sarcopenia are key aspects of aging.
- Age-related changes in body composition, inflammation, and hormones contribute to these conditions.
- Emerging therapies necessitate clear definitions for research and treatment.
Purpose of the Study:
- To highlight the urgent need for a consensual, operational definition of sarcopenia and physical frailty.
- To propose criteria for an operational definition, including muscle mass, strength, and physical activity.
- To emphasize the requirement for clinical validation of proposed definitions.
Main Methods:
- Review of existing literature on sarcopenia and physical frailty definitions.
- Analysis of components contributing to musculoskeletal aging.
- Identification of criteria for an operational definition for clinical trial inclusion.
Main Results:
- Frailty and sarcopenia are distinct but linked correlates of aging.
- Current definitions require clinical validation.
- An operational definition should integrate muscle mass, strength, and physical activity measures.
Conclusions:
- A consensual, operationally defined threshold for sarcopenia and physical frailty is a priority.
- Clinical validation of proposed definitions is essential.
- Linking improvements in strength/activity to clinical outcomes will guide intervention development for frail older adults.
Related Concept Videos
01:19The Effect of Aging on Tissues
Several body functions deteriorate with age. The external signs of aging are easily identifiable. For example, the skin becomes dry, less elastic, and thins out, forming wrinkles. The skin of the face begins to appear looser due to a decrease in the levels of elastic and collagen fibers in the connective tissue. Additionally, melanin production in the hair follicle decreases with age, resulting in gray hair. Moreover, the senses of sight and hearing decline, so glasses and hearing aids may...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:23Cellular Adaptation I: Introduction and Atrophy
Cells can adapt to environmental changes to maintain function and avoid injury, a process called cellular adaptation. Adapted cells exist in a reversible intermediate state with changes in size, number, phenotype, metabolism, or function. These responses help cells meet altered physiological or pathological demands; for example, enlargement of breast and uterine tissues during pregnancy. Early adaptations may enhance function, but persistent stress eventually causes tissue damage.Types of...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...